SEC Filings - Lipella Pharmaceuticals, Inc.

Skip to content

HOME
PIPELINE
- LP-410 for Oral Graft versus Host Disease
- LP-50 for non-muscle invasive bladder cancer
FOR PATIENTS
- Oral Lichen Planus Clinical Trial
  - Oral Lichen Planus Registry
- LP-10 for Hemorrhagic Cystitis (HC)
  - Radiation Cystitis Registry
MANAGEMENT
PUBLICATIONS
INVESTORS
Recent News

SEC FilingsLipella Pharmaceuticals, Inc2023-02-07T19:21:38+00:00

Investors: SEC Filings

Investors

Corporate Overview
SEC Filings
Press Releases
Stock Quote
Events & Presentations
Corporate Governance
FAQ’s
Investor Relations Contact

Lipella Pharmaceuticals Inc. Code of Ethics

CHARTERS:

Audit Committee Charter
Compensation Committee Charter
Nominating and Corporate Governance Charter

Lipella Pharmaceuticals Inc.
7800 Susquehanna St, Suite 505
Pittsburgh, PA 15208
USA

2024 © Copyright - Lipella Pharmaceuticals, Inc.

Close Sliding Bar Area

Recent Posts

A Message from Our CEO, Dr. Jonathan Kaufman
Lipella Pharma Sees Positive Results for LP-10 Phase 2a Trial
Lipella Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock
Announcing Radiation (and Hemorrhagic) Cystitis Patient Registry
Lipella Pharmaceuticals Announces Successful Completion of Pre-IND Type B FDA Meeting Regarding Oral Lichen Planus Drug Candidate

Lipella Pharmaceuticals, Inc.

Phone: 412-894-1853

Email: Get In Touch Via Email

Reach Out

Investors

Corporate Overview
SEC Filings
Press Releases
Stock Quote
Events & Presentations
Corporate Governance
FAQ’s
Investor Relations Contact